Glenmark Unit Files For Netherlands Trial Of Third Autoimmune Antibody
This article was originally published in PharmAsia News
Executive Summary
Glenmark Pharmaceuticals S.A., the India drug maker's Swiss subsidiary, said it is ready for clinical trials of a molecule that could be a treatment of autoimmune diseases.